• Dutch
    • German
  • End of intervention phase of CLEO study reached

    Approximately 3000 patients measured with DeltaScan.

    With our consortium partners (UMC Utrecht, Charité and UZ Leuven and Key Opinion Leaders Prof Slooter, NL; Prof Spies, DE; Prof Milisen, BE) we carried out the international CLEO evaluation study with the purpose to evaluate DeltaScan in daily practice. The study was severely hampered by the COVID-19 pandemic, which made it impossible to reach the required inclusion numbers in the intervention phase of the study. Study sites did however get a good introduction to DeltaScan and most continue to use DeltaScan after their participation in the study. Other positive achievements of CLEO are:

    • Some 3000 patients in ICUs, cardiothoracic surgery ward and geriatric traumatology wards in the Netherlands, Germany and Belgium were measured several times with DeltaScan
    • on all participating departments the awareness for delirium has risen due to the study participation and presentations we gave
    • thousands of nurses made our e-learning Delirium and e-learning Prolira-DeltaScan use
    • hundreds of doctors made our e-learning Delirium and e-learning Prolira-DeltaScan use
    • thousands of nurses performed measurements with DeltaScan

    DeltaScan® is an EU registered trademark (Certificate Nr 018280613)

    Prolira BV
    Headquarters:
    IJsselburcht 3
    6825 BS Arnhem
    The Netherlands


    Visiting address:
    Padualaan 8
    3584 CH Utrecht
    The Netherlands


    T.
    E.W.


    +31 (0)85 060 1656
    info@prolira.com
    www.prolira.com


    Prolira’s privacy statement
    Cookie statement